Zilebesiran
AssetAlso AD-85481, ALN-85481, ALN-AGT01
Silences hepatic angiotensinogen production through RNA interference, reducing renin-angiotensin signaling and blood pressure.
- Stage
- Phase 3
- Modality
- Oligonucleotide
- Target
- AGT
- 3
- Indications
- 2
- Trials
- 1
- Developer
Indications
3High cardiovascular risk
Phase 3, Recruiting, NCT07181109, clinicaltrials.gov, 15 Oct 2026
High risk cardiovascular disease
Phase 3, Recruiting, NCT07181109, clinicaltrials.gov, 15 Oct 2026
Hypertension
Phase 3, Recruiting, NCT07181109, clinicaltrials.gov, 15 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners2
- Trials2
- Evidence for its targets1
- Competitors1
- Signals4
Every asset’s record: target, stage, trials and the evidence behind it.